An interventional study of Promotion of adherence to the MedDiet in Major Depressive Disorder - MDD, sponsored by Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA. Recruiting at 2 sites in Portugal. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Depression with a site in Portugal — 11 open to participants now, 13 under way, none of them phase 3. Depression · Portugal.
Among the 33 studies in Depression with a site in Portugal, this one is the 9th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 21st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →11 of the 33 studies in Depression with a site in Portugal are open now. Recruiting first, the newest first:
Unidade Local de Saúde do Alto Ave, EPE · Sites in Portugal
Ages 18–70
University of Minho · Sites in Portugal
Ages 18+
University Medical Center Groningen · Sites in Portugal, Czechia, Denmark and 1 more country
Ages 18+
University of Évora · Sites in Portugal
Ages 60–105
University of Minho · Sites in Portugal
Ages 18+ · Healthy volunteers
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 111 across the 27 interventional studies, 606 across the 6 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 33 have an industry lead sponsor. The 10 most frequent:
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
2 of the studies in Depression with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT07755839Aveiro UniversityCanCOG®: Pilot Trial of Cognitive Rehabilitation for Cancer Survivors | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Depression with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The hypothesis to be tested by this study is that an intervention promoting adherence to the MedDiet can decrease symptoms of depression in patients with elevated inflammation biomarkers, namely C-reactive protein (CRP) and Interleukin 6 (IL-6) diagnosed with Major Depression Disorder (MDD), under treatment with antidepressant medication for a period of time less than or equal to 6 months.
The main aim of this study is to understand if promoting the adherence to the MedDiet, as an adjuvant strategy in the treatment of MDD, is effective in decreasing symptoms of depression in MDD patients, with elevated levels of inflammation biomarkers.
Other specific objectives of the study are
The study will have a duration of 12 weeks, with a randomized parallel-group open controlled trial design, with two parallel groups with an allocation ratio of 1:1 - (a) intervention arm with six nutritional consultations with a registered nutritionist, promoting adherence to MedDiet, in addition to MDD Treatment-As-Usual (TAU) and (b) control group arm benefitting only from MDD TAU. A follow up assessment will be performed at 6- and 12-months.
Having into consideration an attrition of 40 percentage at the end of the intervention, the minimum sample size estimated is 190 (95 per arm).
The main outcome of the trial, changes in symptoms of depression, will be evaluated using the Beck Depression Inventory Second Edition (BDI-II).
To test the study´s hypothesis, namely if an intervention promoting adherence to the MedDiet can decrease symptoms of depression in patients with MDD and elevated inflammation biomarkers, the following objectives will be assessed.
The main objective of the trial is:
1.To assess the effectiveness of dietary counselling promoting MedDiet, as an adjuvant treatment of MDD, to decrease depressive symptoms in adults diagnosed with MDD and having elevated inflammation biomarkers (CRP, IL-6).
Specific objectives are:
This study is a 12-week multicentre randomized parallel-group open controlled trial, with a follow up assessment at 6- and 12-months after baseline data collection, with two parallel groups with an allocation ratio of 1:1. - (a) intervention arm with six nutrition consultations with a registered nutritionist, promoting adherence to MedDiet, in addition to MDD treatment as usual (TAU) and (b) control group benefitting only from MDD TAU. Participants will be individuals diagnosed with a first episode of MDD, according to the "F32 Depressive episode" (F32.0; F32.1; F32.2) classification of the Tenth Revision of the International Classification of Diseases (ICD-10), under treatment with antidepressant medication for a period of time less than or equal to 6 months, attending to outpatient consultations.
Potential participants will be invited to enrol by their medical doctors from the participating recruitment centres. The invitation will be made at regular medical appointments including primary care consultations and outpatient psychiatric consultations in one of the participant centers. After signing the informed consent, CRP and IL-6 levels will be tested. Participants with increased inflammatory biomarkers, meeting all other inclusion criteria will be randomized to (a) the intervention arm or (b) the control arm of the study, in a 1:1 ratio, using a computer-generated list of random numbers stratified by center in variable blocks of size 2, 4 and 6. Treatment allocation will be concealed from the researchers, using sequentially numbered, opaque, sealed envelopes.
The study will use a convenience sample from patients diagnosed with MDD attending to outpatient consultations in one for the participating clinics.
Considering a 2-sided significance level of 5 percent and a power of 80 percent and having into consideration an attrition of 40 percent at the end of the intervention, the minimum sample size estimated is 190 (95 per arm). Estimating a prevalence of elevated inflammation in 30 percentage of MDD patients and 10 percentage of patients that don't meet other inclusion criteria, the number of recruited participants estimated is 700.
Participants allocated to the intervention group will attend six nutrition consultations, performed by a register nutritionist in weeks 1, 2, 4, 6, 8 and 10. The intervention will be personalized to each participant and will promote adherence to the Mediterranean Diet, ad libitum, without calories or macronutrients restriction or recommendation for weight change.
The intervention will follow a similar approach to the one proposed by Estruch et al. in the "Primary Prevention of Cardiovascular Disease with a Mediterranean Diet" study.
The intervention will contemplate the following recommendations:
Positive recommendations (promotion of the intake of the following foods):
Negative recommendations (eliminate or drastically reduce the following foods):
Training of the nutritionists delivering the intervention will be provided prior to the beginning of recruitment and during the duration of the trial in MDD, therapeutic relationship, trauma and Mediterranean Diet.
Data analysis and reporting will be performed in accordance with Consolidated Standards of Reporting Trials (CONSORT) guidelines.
Primary analysis will include all randomized participants, following an intention-to-treat (ITT) approach. Baseline characteristics of the participants, by group, will be reported using descriptive statistics and compared by χ\^2 and t-test for independent samples (or equivalent non-parametric test).
To evaluate the effectiveness of nutritional counselling promoting MedDiet, the scale BDI-II will be used categorically in accordance with the standardized cutoffs: minimal depression (0-13), mild depression (14-19), moderate depression (20-28), severe depression (29-63). The success measure will be a decrease in category in the severity of depressive symptoms. The proportion of participants with a decrease in depression severity symptoms category according to the BDI-II (main outcome) will be compared between control and intervention groups using generalized linear mixed models.
Further adjustment for relevant covariates, as supportive analysis, will be made. Secondary analyses, including the analysis of the main outcome measure (BDI-II) as a continuous variable, will be conducted using (Generalized) Linear Mixed Models, as appropriate. For each outcome, results for either intervention and control group, and estimates of effect size with a 95 percent confidence interval will be reported. All analyses will be performed using R and R Studio version 3.5.3 and R Studio version 1.3.618 (or another updated version in the moment of analysis), assuming a significance level of 5 percent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interventional group with six nutritional counselling consultations promoting the adherence to the MedDiet and TAU for MDD
Behavioral: Promotion of adherence to the MedDiet
Individuals with TAU for MDD
Participants will be followed in six individual nutrition consultations with a duration of 30 to 60 minutes. The consultations will be focused on promoting the adherence to the MedDiet. The nutritional intervention will be personalized to each individual ad libitum, without calories or macronutrients restriction and without the goal to promote weight change. The intervention will begin with an initial assessment of the dietary patterns of the participants in which the nutritionist will identify potential behavioural changes to promote adjustments in dietary habits and therefore adherence to the MedDiet. The intervention will promote positive recommendations (behaviours recommended to follow) and negative recommendations (behaviours recommended to reduce or eliminate) (26), using the strategy and MedDiet definition proposed by Estruch et al. in the "Primary Prevention of Cardiovascular Disease with a Mediterranean Diet" study (3). The participants will also maintain MDD TAU.
Changes in symptoms of MDD
Symptoms of depression will be assessed with the self-administered Beck Depression Inventory-II (BDI-II) scale. To measure changes in the main outcome, the score of the BDI-II will be used categorically, considering the cut-offs proposed: 0-13 minimal depression; 14-19 mild depression; 20-28 moderate depression; 29-63 severe depression. The success measure will be a downgrade of category in the severity of depressive symptoms. The analysis of the score of the BDI-II will also be performed using the scale score as a continuous variable.
Time frame: Baseline, 12-weeks, 6-months, and 12-months after the baseline assessment
Inflammation biomarkers (IL-6 and/or CRP)
Identification of statistically significant variation of IL-6 and/or CRP concentrations in blood between baseline and other moments of assessment. CRP and IL-6 will be measured using a Atellica CH Analyzer.
Time frame: Baseline, 12-weeks, 6-months, and 12-months after the baseline assessment
Adherence to the Mediterranean Diet according to the 14-point Mediterranean Diet Adherence Screener Scale
The Adherence to the Mediterranean Diet will be assessed by the validated Portuguese version of the 14-point Mediterranean Diet Adherence Screener. This instrument evaluates the intake of foods typical of the MedDiet. The scale presents a result from 0 to 14 points, with a higher score indicating greater adherence to the mediterranean dietary pattern. Changes between baseline and other assessments will be analysed using the score of the scale as a continuous variable..
Time frame: Baseline,12-weeks, 6-months, and 12-months after the baseline assessment
Health-related quality of life
Changes in health-related quality of life between baseline and other assessment moments will be accessed by the World Health Organization Quality of Life - Brief (WHOQOL-BREF). The global score of the scale ranges from 0 to 100 points, with a higher score indicating a higher quality of life.
Time frame: Baseline, 12-week, 6-months, and 12-months after the baseline assessment
Healthcare use cost
The estimation cost of healthcare resource use will be assessed using: number of days of hospital admission, general care medical appointments and specialty medical appointments, sessions of massage and physiotherapy, psychology appointments and ocupational therapy appointments.
Time frame: Baseline,12-weeks, 6-months, and 12-months after the baseline assessment
Absenteeism
Absence from work will be estimated in hours.
Time frame: Baseline,12-weeks, 6-months, and 12-months after the baseline assessment
Plan to share: No
Started Jun 2023 (actual). Primary completion is estimated for Jan 2025, 19 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 19 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA